HIV molecular immunology database
Found 5 matching records:
Download this epitope record as JSON.
HXB2 Location | gp160(33-42) gp120(33-42) DNA(6321..6350) |
gp160 Epitope Map |
---|---|---|
Author Location | Env(32-41 LAI) | |
Epitope |
KLWVTVYYGV
|
Epitope Alignment
|
Epitope Name | Env32-41 | |
Subtype | B | |
Species (MHC/HLA) | human(A*02:01) | |
Immunogen | vaccine | |
Country | United States | |
Experimental methods | Chromium-release assay | |
Keywords | dendritic cells, enhancing activity |
Vaccine type | protein |
---|---|
Vaccine strain | B clade MN |
Vaccine component | gp160 |
Dupuis1995 M. Dupuis, S. K. Kundu, and T. C. Merigan. Characterization of HLA-A*0201-Restricted Cytotoxic T Cell Epitopes in Conserved Regions of the HIV Type 1 gp160 Protein. J. Immunol., 155:2232-2239, 1995. Five HLA-A2 HIV-1 seropositive HIV-1 MN rec gp160 vaccinees had their CTL activity assessed using peptides known to bind with high affinity to HLA-A*0201. Four of the patients had specific CTL activity for a minimum of at least three epitopes, thus the response appears heterogeneous. One of the four peptides was confirmed to be HLA A2 restricted. Epitopes were highly conserved. PubMed ID: 7543542. Show all entries for this paper.
Download this epitope record as JSON.
HXB2 Location | gp160(121-129) gp120(121-129) DNA(6585..6611) |
gp160 Epitope Map |
---|---|---|
Author Location | Env(120-128 LAI) | |
Epitope |
KLTPLCVTL
|
Epitope Alignment
|
Epitope Name | Env120-128 | |
Subtype | B | |
Species (MHC/HLA) | human(A*02:01) | |
Immunogen | vaccine | |
Country | United States | |
Experimental methods | Chromium-release assay | |
Keywords | dendritic cells, enhancing activity, novel epitope |
Vaccine type | protein |
---|---|
Vaccine strain | B clade MN |
Vaccine component | gp160 |
Dupuis1995 M. Dupuis, S. K. Kundu, and T. C. Merigan. Characterization of HLA-A*0201-Restricted Cytotoxic T Cell Epitopes in Conserved Regions of the HIV Type 1 gp160 Protein. J. Immunol., 155:2232-2239, 1995. Five HLA-A2 HIV-1 seropositive HIV-1 MN rec gp160 vaccinees had their CTL activity assessed using peptides known to bind with high affinity to HLA-A*0201. Four of the patients had specific CTL activity for a minimum of at least three epitopes, thus the response appears heterogeneous. One of the four peptides was confirmed to be HLA A2 restricted. Epitopes were highly conserved. PubMed ID: 7543542. Show all entries for this paper.
Download this epitope record as JSON.
HXB2 Location | gp160(813-822) gp41(302-311) DNA(8661..8690) |
gp160 Epitope Map |
---|---|---|
Author Location | Env(814-823 LAI) | |
Epitope |
SLLNATDIAV
|
Epitope Alignment
|
Show epitope variants | ||
Epitope Name | Env814-823 | |
Subtype | B | |
Species (MHC/HLA) | human(A*02:01) | |
Immunogen | vaccine | |
Country | United States | |
Experimental methods | Chromium-release assay | |
Keywords | dendritic cells, enhancing activity, optimal epitope, novel epitope |
Vaccine type | protein |
---|---|
Vaccine strain | B clade MN |
Vaccine component | gp160 |
Dupuis1995 M. Dupuis, S. K. Kundu, and T. C. Merigan. Characterization of HLA-A*0201-Restricted Cytotoxic T Cell Epitopes in Conserved Regions of the HIV Type 1 gp160 Protein. J. Immunol., 155:2232-2239, 1995. Five HLA-A2 HIV-1 seropositive HIV-1 MN rec gp160 vaccinees had their CTL activity assessed using peptides known to bind with high affinity to HLA-A*0201. Four of the patients had specific CTL activity for a minimum of at least three epitopes, thus the response appears heterogeneous. One of the four peptides was confirmed to be HLA A2 restricted. Epitopes were highly conserved. PubMed ID: 7543542. Show all entries for this paper.
Download this epitope record as JSON.
HXB2 Location | gp160(814-822) gp41(303-311) DNA(8664..8690) |
gp160 Epitope Map |
---|---|---|
Author Location | Env(815-823 LAI) | |
Epitope |
LLNATDIAV
|
Epitope Alignment
|
Epitope Name | Env815-823 | |
Subtype | B | |
Species (MHC/HLA) | human(A*02:01) | |
Immunogen | vaccine | |
Country | United States | |
Experimental methods | Chromium-release assay | |
Keywords | dendritic cells, enhancing activity, optimal epitope, novel epitope |
Vaccine type | protein |
---|---|
Vaccine strain | B clade MN |
Vaccine component | gp160 |
Dupuis1995 M. Dupuis, S. K. Kundu, and T. C. Merigan. Characterization of HLA-A*0201-Restricted Cytotoxic T Cell Epitopes in Conserved Regions of the HIV Type 1 gp160 Protein. J. Immunol., 155:2232-2239, 1995. Five HLA-A2 HIV-1 seropositive HIV-1 MN rec gp160 vaccinees had their CTL activity assessed using peptides known to bind with high affinity to HLA-A*0201. Four of the patients had specific CTL activity for a minimum of at least three epitopes, thus the response appears heterogeneous. One of the four peptides was confirmed to be HLA A2 restricted. Epitopes were highly conserved. PubMed ID: 7543542. Show all entries for this paper.
Download this epitope record as JSON.
HXB2 Location | gp160(828-836) gp41(317-325) DNA(8706..8732) |
gp160 Epitope Map |
---|---|---|
Author Location | Env(829-837 LAI) | |
Epitope |
RVIEVLQRA
|
Epitope Alignment
|
Epitope Name | Env829-837 | |
Subtype | B | |
Species (MHC/HLA) | human(A*02:01) | |
Immunogen | vaccine | |
Country | United States | |
Experimental methods | Chromium-release assay | |
Keywords | dendritic cells, enhancing activity |
Vaccine type | protein |
---|---|
Vaccine strain | B clade MN |
Vaccine component | gp160 |
Dupuis1995 M. Dupuis, S. K. Kundu, and T. C. Merigan. Characterization of HLA-A*0201-Restricted Cytotoxic T Cell Epitopes in Conserved Regions of the HIV Type 1 gp160 Protein. J. Immunol., 155:2232-2239, 1995. Five HLA-A2 HIV-1 seropositive HIV-1 MN rec gp160 vaccinees had their CTL activity assessed using peptides known to bind with high affinity to HLA-A*0201. Four of the patients had specific CTL activity for a minimum of at least three epitopes, thus the response appears heterogeneous. One of the four peptides was confirmed to be HLA A2 restricted. Epitopes were highly conserved. PubMed ID: 7543542. Show all entries for this paper.